Discard or not discard, that is the question: an international survey across 117 embryologists on the clinical management of borderline quality blastocysts.


Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
03 10 2023
Historique:
received: 19 06 2023
revised: 02 08 2023
medline: 4 10 2023
pubmed: 31 8 2023
entrez: 31 8 2023
Statut: ppublish

Résumé

Do embryologists from different European countries agree on embryo disposition decisions ('use' or 'discard') about Day 7 (>144 h post-insemination) and/or low-quality blastocysts (LQB; <Gardner's BB) (i.e. borderline quality blastocysts)? The prevalence of 'discard' answers was 38.7%; nevertheless, embryologists' agreement was overall just fair (Fleiss-k = 0.26). The utilization of LQBs and adoption of culture beyond 144 h post-insemination is increasing worldwide. Although morphology and morphokinetics are associated with embryo developmental competence, previous studies demonstrated significant interobserver variability among embryologists regarding embryo quality assessment and disposition decisions for borderline quality blastocysts. An anonymous survey was run in a large network of IVF centers. A total of 117 embryologists from 6 European countries and 29 IVF centers filled in the survey. Randomly selected anonymous time-lapse videos of 50 Day 7 and/or LQB whole embryo preimplantation development were assessed by the embryologists. The key information on patients/cycles was provided along with each video. All cycles entailed preimplantation genetic testing for aneuploidies. Each embryologist specified whether he/she would have discarded or used ('transfer-fresh'/'cryopreserve'/'biopsy') any embryo. Inter-rater agreement was measured with Fleiss-k. Examiners were asked about their years of experience, center location, average number of cycles and average maternal age, number of colleagues, and use of time-lapse incubators at their centers. All participants were blinded to artificial intelligence (AI) scores generated by two commercially available software packages, chromosomal diagnosis (all blastocysts were tested for aneuploidies), and clinical outcomes after vitrified-warmed euploid single blastocyst transfer. These data were known only by one embryologist not involved in the survey. Participants were Italian (40%, N = 47), Spanish (24%, N = 28), Portuguese (5%, N = 6), Czech (5%, N = 6), Swedish (23%, N = 27), and Icelandic (3%, N = 3). In total, 2263 (38.7%) 'discard' and 3587 (61.3%) 'use' decisions were recorded. Czech, Portuguese, and Italian embryologists expressed lower 'discard' decision rates (mean ± SD 17 ± 7%, range 8-24%; 23 ± 14% range 4-46%; and 27 ± 18% range 2-72%, respectively), while Spanish gave intermediate (37 ± 16% range 4-66%) and Nordic gave higher (67 ± 11% range 40-90%) rates. The prevalence of 'discard' answers was 38.7% out of 5850 choices (mean per embryologist: 39 ± 23% range 2-90%). Only embryologists' country and IVF group were associated with this rate. Overall agreement among embryologists was fair (Fleiss-k = 0.26). The prevalence of 'discard' responses per embryo was 37 ± 24% (range 2-87%). Only the number of sibling blastocysts influenced this rate (i.e. the larger the cohort, the higher the inclination to 'discard'). No difference was shown for the two scores between euploid and aneuploid borderline quality blastocysts, while the embryologists were, by chance, more prone to 'discard' the latter (28.3 ± 21% range 9-71% versus 41.6 ± 24.8% range 2-87%, respectively). The survey included only private IVF clinics located in Europe. Moreover, a key variable is missing, namely patients' access to care. Indeed, all embryologists involved in the survey were part of the same network of private IVF clinics, while the embryo disposition decisions might be different in a public setting. Decision-making by European embryologists regarding Day 7 embryos or LQBs is inconsistent with putative clinical consequences, especially in patients with low prognosis. Although the embryologists could make decisions independent from their local regulations, their mindset and clinical background influenced their choices. In the future, AI tools should be trained to assess borderline quality embryos and empowered with cost-effectiveness information to support embryologists' decisions with more objective assessments. No external funding was obtained for this study. The authors have no conflict of interest to declare. N/A.

Identifiants

pubmed: 37649342
pii: 7256337
doi: 10.1093/humrep/dead174
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1901-1909

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Viviana Chiappetta (V)

IVIRMA Global Research Alliance, GENERA, Clinica Valle Giulia, Rome, Italy.

Federica Innocenti (F)

IVIRMA Global Research Alliance, GENERA, Clinica Valle Giulia, Rome, Italy.

Giovanni Coticchio (G)

IVIRMA Global Research Alliance, 9.baby, Bologna, Italy.

Aisling Ahlström (A)

IVIRMA Global Research Alliance, LIVIO, Göteborg, Sweden.

Laura Albricci (L)

IVIRMA Global Research Alliance, GENERA, Clinica Valle Giulia, Rome, Italy.

Vicente Badajoz (V)

IVIRMA Global Research Alliance, GINEFIV, Madrid, Spain.

Maria Hebles (M)

IVIRMA Global Research Alliance, GINEMED, Sevilla, Spain.

Miguel Gallardo (M)

IVIRMA Global Research Alliance, GINEMED, Lisbon, Portugal.

Francesca Benini (F)

IVIRMA Global Research Alliance, DEMETRA, Florence, Italy.

Stefano Canosa (S)

IVIRMA Global Research Alliance, LIVET, Turin, Italy.

Jiří Kumpošt (J)

IVIRMA Global Research Alliance, FERTICARE, Prague, Czech Republic.

Katarina Milton (K)

IVIRMA Global Research Alliance, CARL VON LINNÈ KLINIKEN, Uppsala, Sweden.

Diletta Montanino Oliva (D)

Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy.

Roberta Maggiulli (R)

IVIRMA Global Research Alliance, GENERA, Clinica Valle Giulia, Rome, Italy.

Laura Rienzi (L)

IVIRMA Global Research Alliance, GENERA, Clinica Valle Giulia, Rome, Italy.
Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.

Danilo Cimadomo (D)

IVIRMA Global Research Alliance, GENERA, Clinica Valle Giulia, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH